Highlights
- Dr. Reddy’s shares gained 1.59% to close at INR 1,350.50 in latest session.
- Company reported consolidated net profit of INR 22,130.00 lakh for March 2026 quarter.
- Stock trades near its 52-week high of INR 1,375.90 after recent upward move.
Dr. Reddy’s Laboratories Limited (NSE:DRREDDY), listed on the National Stock Exchange (NSE) under the pharmaceuticals sector, closed at INR 1,350.50 on June 25, 2026, registering a gain of INR 22.10 or 1.66% from the previous close.
The stock opened at INR 1,331.90 and moved within a tight range, touching an intraday high of INR 1,363.00 and a low of INR 1,331.90. The Volume Weighted Average Price (VWAP) stood at INR 1,351.57, closely aligned with the closing price.
Source: Analysis by Kalkine
Trading Activity and Market Position
Dr. Reddy’s recorded traded volume of 17.00 lakh shares with a traded value of INR 229.73 crore during the session. The impact cost was low at 0.02, indicating efficient liquidity in the counter.
The company’s total market capitalisation stood at INR 1,12,638.59 crore, while free-float market capitalisation was INR 82,008.67 crore, reflecting significant institutional participation. Deliverable quantity accounted for 46.77% of total traded volume, indicating balanced participation between delivery and intraday traders.
Stock Performance Across Time Frames
Dr. Reddy’s has shown mixed performance relative to the NIFTY 50 index. Over the past week, the stock gained 6.08%, significantly outperforming the index, which rose 0.18%. On a one-month basis, the stock gained 1.63% compared with the index gain of 0.60%.
Year-to-date performance shows a gain of 7.67%, while the NIFTY 50 index declined 8.00% during the same period, indicating relative outperformance. Over a one-year period, the stock has risen 2.12%, while the index declined 5.84%. Longer-term returns include 33.84% over three years and 27.09% over five years.
The stock is currently trading close to its 52-week high of INR 1,375.90, recorded on April 29, 2026, while the 52-week low stands at INR 1,148.40.
Financial Performance Overview
For the quarter ended March 31, 2026, Dr. Reddy’s reported standalone total income of INR 4,38,920.00 lakh. However, standalone performance showed a loss before tax of INR 30,550.00 lakh and a net loss of INR 21,940.00 lakh, with earnings per share of INR -2.63.
On a consolidated basis, total income stood at INR 8,02,180.00 lakh. Profit before tax was INR 19,510.00 lakh, while net profit stood at INR 22,130.00 lakh. Consolidated EPS was reported at INR 2.65.
Valuation and Market Position
Dr. Reddy’s Laboratories is part of the NIFTY 50 index and operates in the Pharmaceuticals industry. The stock’s P/E ratio stands at 27.20, reflecting market expectations for earnings growth in the sector.
The stock continues to show relatively lower volatility at 27.70 annualised, compared with broader market swings.
Key Risks
- Currency fluctuations may impact export-driven revenue streams.
- Regulatory approvals in key markets can affect product pipeline timelines.
- Pricing pressure in generic drugs may reduce margins.
- Research and development costs may increase earnings variability.
Summary
Dr. Reddy’s Laboratories (NSE:DRREDDY) shares ended higher at INR 1,350.50 on June 25, 2026, gaining 1.59% amid steady market activity. While consolidated results showed a profit of INR 22,130.00 lakh, standalone results reported a loss. The stock continues to trade near its 52-week high with mixed financial signals.
FAQs
Q: What was Dr. Reddy’s closing price on June 25, 2026?
A: The stock closed at INR 1,350.50 after gaining 1.59% during the session.
Q: What was Dr. Reddy’s consolidated net profit for March 2026 quarter?
A: The company reported consolidated net profit of INR 22,130.00 lakh.
Q: How has Dr. Reddy’s performed compared to NIFTY 50 index?
A: The stock outperformed the index year-to-date with a gain of 7.67% versus index decline.